Leidos names Michael Jackman as new Health Group Chief Operating Officer

RESTON, Va., Jan. 23, 2020 /PRNewswire/ — Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, announced today that Michael Jackman has been named the Leidos Health Group’s chief operating officer (COO). In his new role, Jackman will oversee the day-to-day operations of the Health Group while working in close collaboration with the group’s leadership team to deliver a range of solutions and services designed to meet today’s healthcare challenges.

Prior to joining Leidos, Jackman served as an operating partner at Ardan Equity Partners, a private equity firm exclusively focused on healthcare enterprise software. His primary responsibility consisted of collaborating with health executives to build platforms designed to accelerate company growth. Before that, Jackman was chief executive officer of Mach7 Technologies, where he led the business in health imaging modernization, enterprise data sharing, and patient data consolidation.

Jackman also served as the leader for the Americas Region of GE Healthcare’s Digital HCIT Division, where he oversaw the HCIT business in Latin America, the U.S., and Canada. He has also held executive roles for Carestream Health, iSOFT Health Group, and Eastman Kodak where he led Kodak healthcare research and development (R&D) globally. Jackman’s career started at IBM where he was vice president of Systems and Technology for the IBM Personal Systems Group for close to two decades.

“Michael is a growth-minded leader with decades of executive experience in healthcare systems optimization,” said Jon Scholl, Leidos Health Group president. “His previous administration of digital transformation and healthcare R&D initiatives will be instrumental in our long-term growth strategy.”

“I am thrilled to join an organization that leverages technology to enhance the continuum of care from research laboratory to patient bedside,” said Michael Jackman, the new chief operating officer for the Leidos Health Group. “I look forward to introducing expertise that will further improve clinical, operational, and financial outcomes for our customers’ important work.”

Michael holds a Master’s of Business Administration from Nova Southeastern University and an undergraduate degree from the University of Rhode Island in electrical and electronics engineering.

About Leidos

Leidos is a Fortune 500® information technology, engineering, and science solutions and services leader working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company’s 34,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $10.19 billion for the fiscal year ended December 28, 2018. For more information, visit www.Leidos.com.  

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company’s Annual Report on Form 10-K for the period ended December 28, 2018, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Contact:         

Melissa Koskovich   
(571) 526-6011
Koskovichm@Leidos.com                            

Suzzanna Martinez
(303) 299-5343
suzzanna.m.martinez@leidos.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/leidos-names-michael-jackman-as-new-health-group-chief-operating-officer-300992334.html

SOURCE Leidos

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

10 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

13 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

13 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

13 hours ago